# A Study to Gather Information About Rivaroxaban in Patients in the United Kingdom Who Have Cancer and Thrombosis (OSCAR-UK)

> **NCT05112666** · — · COMPLETED · sponsor: **Bayer** · enrollment: 2601 (actual)

## Conditions studied

- Treatment of Venous Thromboembolism in Cancer Patients

## Interventions

- **DRUG:** Rivaroxaban (Xarelto, BAY59-7939)
- **DRUG:** other DOACs
- **DRUG:** LMWH

## Key facts

- **NCT ID:** NCT05112666
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-02
- **Primary completion:** 2022-08-26
- **Final completion:** 2022-08-26
- **Target enrollment:** 2601 (ACTUAL)
- **Last updated:** 2023-04-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05112666

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05112666, "A Study to Gather Information About Rivaroxaban in Patients in the United Kingdom Who Have Cancer and Thrombosis (OSCAR-UK)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05112666. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*